NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LXRX shares have decreased by 11.5% and is now trading at $2.01. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its earnings results on Monday, April, 27th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.69) by $0.06. The biopharmaceutical company earned $8 million during the quarter, compared to the consensus estimate of $7.18 million. Lexicon Pharmaceuticals had a return on equity of 125.61% and a net margin of 26.59%. View Lexicon Pharmaceuticals' earnings history.

6 analysts have issued 12 month price targets for Lexicon Pharmaceuticals' stock. Their forecasts range from $2.10 to $9.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $4.53 in the next year. This suggests a possible upside of 125.1% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals.

Media stories about LXRX stock have been trending negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutLexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 10,520,000 shares, a decrease of 5.9% from the April 15th total of 11,180,000 shares. Based on an average daily trading volume, of 950,600 shares, the short-interest ratio is presently 11.1 days. Currently, 10.2% of the shares of the stock are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), Orexigen Therapeutics (OREX), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Micron Technology (MU).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.76%), AQR Capital Management LLC (1.35%), Pictet Asset Management Ltd. (1.12%), Acadian Asset Management LLC (1.01%), State Street Corp (0.77%) and Bank of New York Mellon Corp (0.70%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Morgan Stanley, Spark Investment Management LLC, AXA, State Street Corp, Bank of New York Mellon Corp, Pinnacle Associates Ltd., and BlackRock Inc.. View insider buying and selling activity for Lexicon Pharmaceuticals.

LXRX stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, AQR Capital Management LLC, Federated Hermes Inc., Pictet Asset Management Ltd., Hancock Whitney Corp, WINTON GROUP Ltd, Squarepoint Ops LLC, and Two Sigma Advisers LP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus, and Sam L Barker. View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $2.01.

Lexicon Pharmaceuticals has a market capitalization of $215.01 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.